HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

SurgiMab – Phase 3 Trial Evaluating a Novel Fluorescent Tumor-specific Antibody for the Improvement of Surgical Outcomes in Colorectal Cancer Patients

by admin | Oct 28, 2019 | Clinical Trials

SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, announces that the first US patient has been recruited into its on-going pivotal Phase...
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies bacteria binx health Biosimilar Blood Filter Cancer cardiovascular cell therapy CE Mark clinical trial colorectal cancer Diagnostics Digital Health Drug Discovery ExThera Medical FDA FDA approval funding fundraising glycosylation Halodoc HIV Innovation Licensing M&A medical device medtech microbial microbial DNA microbial RNA microbiome Neuro Novartis pharma Pharming Prescient Metabiomics robots software Therapeutics Therapy USA VIrology women health

Home
Activities
Our Team
Contact Us

         contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.